TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02147353
Drug: Cryotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy will be standardized in all subjects and for all treated lesions.
Study: NCT02745392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
Study: NCT02949960
Drug: DMT210 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT210 Topical Aqueous Gel 5% applied twice daily
Study: NCT02045966
Drug: Cocktail
Normalized name: Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
Study: NCT02045966
Drug: DCV 3DAA FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
Study: NCT01033643
Drug: MK-3614
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
Study: NCT01033643
Drug: Placebo for MK-3614
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were administered dose matched placebo tablets according to randomization.
Study: NCT02823743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake
Study: NCT00116142
Drug: Androgen Suppression Therapy and Radiation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Androgen Ablation and External Beam Radiation Therapy
Study: NCT03840239
Drug: Capecitabine, Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Capecitabine, Oxaliplatin
Study: NCT00892723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT00892723
Drug: AZX100 Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT03599960
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)
Study: NCT00426153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
Study: NCT03507790
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Study Drug
Study: NCT03507790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active study drug
Study: NCT01613118
Drug: RE-021 (Sparsentan)
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once-daily
Study: NCT04854668
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
Study: NCT01313689
Drug: Physicians' Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
Study: NCT01421771
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator
Study: NCT00125918
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet taken by mouth once a day for 16 weeks
Study: NCT04005872
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
Study: NCT04186156
Drug: KA2507
Approvals — FDA: no, EMA: no, PMDA: no
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Study: NCT03422978
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose normal saline administered over 60 seconds post-induction.
Study: NCT02181959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02402972
Drug: oxaliplatin+Leucovorin+5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
Study: NCT00887432
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04160767
Drug: Probiotic Vivomixx
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
Study: NCT00629512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01026493
Drug: ABT-888 20 mg x 21 days
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
Study: NCT01026493
Drug: ABT-888 40 mg x 21 days
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
Study: NCT01026493
Drug: ABT-888 40 mg x 5 days
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Study: NCT04655313
Drug: ARQ-151 cream 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Study: NCT00743405
Drug: GSK1034702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or liquid
Study: NCT00743405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match GSK1034702
Study: NCT00451698
Drug: acyanotic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV push
Study: NCT05002179
Drug: Echinaforce Chewable tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution.
Study: NCT01209676
Drug: IMCgp100 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: a monoclonal T cell receptor anti-CD3scFv fusion protein
Study: NCT01445756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; no topical lidocaine administered
Study: NCT04408183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given as a nasal spray using an atomizer
Study: NCT03369990
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT00551460
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00551460
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01014260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
Study: NCT01014260
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
Study: NCT02803892
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
Study: NCT02803892
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
Study: NCT01808482
Drug: Part A: 100 mg/mL GSK2618960
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
Study: NCT01808482
Drug: Part A: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01808482
Drug: Part B: Dose of GSK2618960 decided from Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
Study: NCT01808482
Drug: Part B: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01808482
Drug: Part C: Dose of GSK2618960 decided from Part A and B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
Study: NCT01206764
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03343548
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cc of normal saline will be administered epidurally
Study: NCT02294266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose placebo
Study: NCT00833326
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, escalating
Study: NCT00833326
Drug: Prophylactic growth factors; subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care
Study: NCT00005649
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00256451
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT04600349
Drug: Treatment as Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Study: NCT01703468
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00747214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00747214
Drug: DMARD Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD therapy can include methotrexate or other DMARD therapy
Study: NCT00771368
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
Study: NCT02718937
Drug: Matching placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04451083
Drug: FOY-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose of FOY-305 will be administered orally at 4 times/day.
Study: NCT01498289
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
Study: NCT01498289
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
Study: NCT01498289
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Study: NCT00004261
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00833755
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Study: NCT00125502
Drug: MF59 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-in-water emulsion
Study: NCT00125502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution
Study: NCT02182557
Drug: WAL 801 CL Dry Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182557
Drug: WAL 801 CL Dry Syrup placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00221741
Drug: Fresh Frozen Plasma (blood product)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00244439
Drug: MALG
Normalized name: Amalgam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minute application
Study: NCT00244439
Drug: Ovide (malathion) lotion 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-12 hour application
Study: NCT04163874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
Study: NCT00981617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once daily for 12 weeks
Study: NCT01387269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
Study: NCT03054402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo
Study: NCT03172676
Drug: Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.
Approvals — FDA: no, EMA: no, PMDA: no
Description: chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
Study: NCT01222299
Drug: placebo comparator nasal product
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile nasal product
Study: NCT03794778
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m2, i.v.,d1; once every 21days
Study: NCT00562965
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
Study: NCT00847093
Drug: LMX4 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One inch every six hours
Study: NCT01972711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose placebo
Study: NCT00031551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01354925
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care during Ramadan according to physicians decision
Study: NCT00004233
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004233
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00492011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
Study: NCT00416273
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the observation group will be observed and will not receive any consolidation therapy.
Study: NCT00846365
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Study: NCT00846365
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Study: NCT02754258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 days on oral placebo administered 2 times daily before lunch and supper
Study: NCT01806415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo or lactose 150 mg
Study: NCT00252993
Drug: DDP225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03131141
Drug: BC-3781
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
Study: NCT01124617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
Study: NCT02857868
Drug: ABL001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03133676
Drug: KA34
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 µg - 400 µg intra-articular injection (single or multiple doses)
Study: NCT03133676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg - 400 µg intra-articular injection (single or multiple doses)
Study: NCT00392106
Drug: sotolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
Study: NCT01813422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT01653743
Drug: MSJ-0011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
Study: NCT03704298
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT00873353
Drug: capecitabine + erlotinib
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days
Study: NCT01403610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
Study: NCT00547261
Drug: SSR97225
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 3 weeks
Study: NCT03610633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution.
Study: NCT01782339
Drug: Combination Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle.